Executive Summary
In a procedural application concerning security for costs, the UPC Central Division dismissed Microsoft Corporation's request to increase the required financial guarantee against Suinno Mobile & AI Technologies Licensing Oy. Although Microsoft argued that increased litigation complexity and the respondent's admitted financial strain warranted higher security, the Court found no new circumstances justifying an amendment. This decision reinforces the principle that initial assessments of recoverable costs, based on the claimant's objective interest at filing, remain relevant even as proceedings progress.
What the Court Held — Ratio Decidendi
The UPC ruled that the progression of the written procedure and the respondent's financial difficulties were not sufficient grounds to reassess or increase the existing security for costs. The court maintained that the original security amount adequately addressed the risk of non-recovery of costs, based on the objective interest stated in the initial statement of claim.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Paris (FR) Central Division - Seat. Understanding the court's reasoning in Microsoft Corporation vs Suinno Mobile & AI Technologies Licensing Oy is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Dainese S.p.A.vsAlpinestars Research S.p.A., ULRICH HERPICH E.K, Alpinestars S.p.A., OMNIA RETAIL S.R.L. , HORIZON MOTO 95 - MAXXESS CERGY, MOTOCARD BIKE, S.L.
This procedural order in a UPC case addressed the claimant's request for protection of confidential information. The Court found that the submitted documents met the criteria for confidentiality, recognizing their economic value and non-public nature. Crucially, the ruling balanced the fundamental right to be heard against the need to protect trade secrets by strictly limiting access to specific individuals from the involved defendants.
Dolby International ABvsEpson France SAS
In this UPC case, Dolby International AB sued Epson France SAS (among others) for alleged infringement of EP 3 605 534B1. The defense raised a preliminary objection arguing that the court lacked jurisdiction because the claimant's withdrawal from the Opt-out regime was invalid. The Local Division of Hamburg dismissed this opposition, finding that the procedural requirements had been met and allowing the case to proceed. This decision clarifies the strict procedural requirements for managing opt-outs within the UPC framework.
Nanoval GmbH & Co. KGvsALD Vacuum Technologies GmbH
This UPC decision addresses procedural issues concerning evidence preservation and deadlines under Rule 198.1 EPGVerfO. The respondent sought to nullify an order because they argued that a change in the deadline's starting point constituted an impermissible extension of time. The court rejected this argument, emphasizing that judicial discretion allows for adjusting the start date when expert reports are delayed. This ruling confirms the flexibility of procedural rules to ensure fair access to evidence.
STADAPHARM GmbHvsACCORD HEALTHCARE S.L.U., ACCORD HEALTHCARE LIMITED, Novartis AG, ACCORD HEALTHCARE B.V.
This UPC Court of Appeal decision addresses the scope of public access to court documents, specifically written pleadings and evidence. Stadapharm appealed a lower court's denial of access to documents from a withdrawn main infringement proceeding. The Court ultimately granted access, emphasizing that once proceedings are concluded and parties consent or do not object, the general interest in public access prevails. This ruling provides clarity on how confidentiality concerns must be balanced against transparency requirements within the UPC framework.
Boehringer Ingelheim International GmbHvsZentiva Portugal, LDA.
In a significant decision regarding generic drug competition, the UPC Court of Appeal granted provisional measures in favor of Boehringer Ingelheim against Zentiva. The court held that the completion of national health technology assessments and reimbursement procedures for generics can constitute an imminent infringement threat, even before market launch. This ruling reinforces the proactive nature of the UPC's jurisdiction across all member states, providing a strong deterrent against premature generic entry.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.